Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 6/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | TYMS | P04818 | 1/20 | 0.44 |
| ▸ | PFKFB3 | Q16875 | 3/20 | 0.44 |
| ▸ | SLC16A3 | O15427 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3554439 | 0.89 | PFKFB3 (0.53) | HTR6TYMSPFKFB3SLC16A3THRB | |
| SCHEMBL3561797 | 0.89 | HDAC1 (0.45) | HTR6TYMSSLC16A3ALDH1A1ADRB2 | |
| SCHEMBL3563480 | 0.88 | HTR6 (0.46) | HTR6KEAP1NFE2L2SLC16A3ALDH1A1 | |
| SCHEMBL3561338 | 0.86 | HTR6 (0.62) | HTR6KEAP1NFE2L2PFKFB3SLC16A3 | |
| SCHEMBL3562342 | 0.85 | HTR6 (0.48) | HTR6KEAP1NFE2L2TYMSPFKFB3 | |
| SCHEMBL3553027 | 0.83 | MEN1 (0.45) | SLC16A3ALDH1A1 | |
| SCHEMBL3561772 | 0.82 | ALDH1A1 (0.62) | ALDH1A1 | |
| SCHEMBL3559525 | 0.82 | SLC16A3 (0.65) | PFKFB3SLC16A3 | |
| SCHEMBL3556902 | 0.81 | MEN1 (0.51) | TYMSPFKFB3SLC16A3THRB | |
| SCHEMBL3552311 | 0.81 | HTR6 (0.44) | HTR6KEAP1NFE2L2PFKFB3SLC16A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | HTR6 2387/4885KEAP1 1284/4885NFE2L2 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.